A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

NCT03637491

Last updated date
Study Location
Institut Jules Bordet
Brussels, , 1000, Belgium
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pancreatic Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent as follows:

1. Metastatic pancreatic ductal adenocarcinoma; or

2. Phase 2 only: Stage IIIb/IV NSCLC or other advanced solid tumors with documented positive KRAS or NRAS mutation as determined using a validated test performed in a CAP/CLIA-certified laboratory (or other comparable local or regional certification).

- Have had disease progression during or following at least 1 and not more than 2 prior lines of treatment for advanced or metastatic disease.

- Patients with NSCLC must have previously received treatment with an anti-PD-1 or anti-PD-L1 agent for advanced disease.

- Measurable disease as per RECIST v1.1 criteria.

- Provision of a baseline tumor sample.

- Age ≥18 years (Japanese patients must be ≥20 years old)

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.

- Adequate bone marrow, renal and liver functions.

- Adequate cardiac function.

- Informed consent provided.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Prior treatment with avelumab, a PARP inhibitor or MEK inhibitor.


- Prior systemic anti-cancer therapy within 2 weeks prior to study enrollment.


- Persisting toxicity related to prior therapy.


- Current use of immunosuppressive medication.


- Known history of immune-mediated colitis, inflammatory bowel disease, pneumonitis,
pulmonary fibrosis, uveitis or iritis.


- Active or prior autoimmune disease that might deteriorate when receiving an
immunostimulatory agent.


- Diagnosis of myelodysplastic syndrome (MDS).


- Known symptomatic brain metastases requiring steroids.


- Known history of testing positive for HIV or hepatitis.


- Clinically significant (ie, active) cardiovascular disease.


- History of thromboembolic or cerebrovascular events.


- Current or anticipated use of a P-gp inhibitor, inducer, or inhibitor of breast cancer
resistance protein (BCRP)


- Uncontrolled hypertension.


- Concurrent neuromuscular disorder that is associated with the potential of elevated
creatinine kinase.


- Known history of Gilbert's syndrome.


- History or current evidence of retinal degenerative disease, retinal vein occlusion
(RVO) or current risk factors for RVO.


- Other acute or chronic medical or psychiatric condition.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pancreatic CancerGemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
NCT00004861
  1. Los Angeles, California
  2. Tampa, Florida
  3. Baltimore, Maryland
  4. Royal Oak, Michigan
  5. Raleigh, North Carolina
  6. Cincinnati, Ohio
  7. Cleveland, Ohio
  8. Memphis, Tennessee
  9. Nashville, Tennessee
  10. Tyler, Texas
  11. Fairfax, Virginia
  12. Winnipeg, Manitoba
  13. Halifax, Nova Scotia
  14. London, Ontario
  15. Ottawa, Ontario
  16. Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pancreatic CancerA Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
NCT03637491
  1. Brussels,
  2. Gent,
  3. Singapore,
  4. Singapore,
  5. Singapore,
  6. Singapore,
  7. Singapore,
  8. Fayetteville, Arkansas
  9. Rogers, Arkansas
  10. Encinitas, California
  11. San Marcos, California
  12. Aurora, Colorado
  13. Aurora, Colorado
  14. Lafayette, Indiana
  15. Pittsburgh, Pennsylvania
  16. Pittsburgh, Pennsylvania
  17. Houston, Texas
  18. Salt Lake City, Utah
  19. Salt Lake City, Utah
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
Official Title  ICMJE A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF COMBINATIONS OF AVELUMAB, BINIMETINIB AND TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RAS-MUTANT SOLID TUMORS
Brief Summary This Phase 1b/2 study will examine the effects of the study drugs, avelumab, binimetinib and talazoparib when given in a 2 (doublet) or 3 (triplet) drug combination, in patients with locally advanced or metastatic RAS-mutant solid tumors. The Phase 1b part of the study will assess if the different study drugs can be given together safely and which doses to use for further research. Phase 2 will test if the study treatments have an effect on tumor size and growth, and gather more information about potential side effects.
Detailed Description

This is a Phase 1b/2, open label, multi-center, safety, clinical activity, pharmacokinetic (PK), and pharmacodynamics (PD) study of combinations of avelumab, binimetinib and talazoparib in adult patients with metastatic pancreatic ductal adenocarcinoma and other locally advanced or metastatic KRAS- or NRAS-mutant solid tumors.

The Phase 1b part of this study will initially assess doublet drug combinations to determine a recommended dose for further investigation. Following this, the recommended dose for the combination of avelumab, binimetinib and talazoparib (triplet) will be determined. The recommended doses for the doublet and triplet combinations will be used in the Phase 2 part of the study, which will assess the safety and preliminary anti-tumor activity of the study treatments.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Pancreatic Cancer
Intervention  ICMJE
  • Drug: Avelumab
    IV treatment
    Other Name: MSB0010718C
  • Drug: Binimetinib
    Oral treatment
    Other Names:
    • MEK162
    • ARRY-438162
  • Drug: Talazoparib
    Oral treatment
    Other Name: MDV3800, BMN 673
Study Arms  ICMJE
  • Experimental: Avelumab and binimetinib
    Open label
    Interventions:
    • Drug: Avelumab
    • Drug: Binimetinib
  • Experimental: Avelumab, binimetinib and talazoparib
    Open label
    Interventions:
    • Drug: Avelumab
    • Drug: Binimetinib
    • Drug: Talazoparib
  • Experimental: Binimetinib and talazoparib.
    Open label.
    Interventions:
    • Drug: Binimetinib
    • Drug: Talazoparib
Publications * Sun C, Fang Y, Labrie M, Li X, Mills GB. Systems approach to rational combination therapy: PARP inhibitors. Biochem Soc Trans. 2020 May 7. pii: BST20191092. doi: 10.1042/BST20191092. [Epub ahead of print]

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 9, 2019)
122
Original Estimated Enrollment  ICMJE
 (submitted: August 16, 2018)
127
Estimated Study Completion Date  ICMJE October 16, 2023
Estimated Primary Completion Date April 19, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent as follows:

    1. Metastatic pancreatic ductal adenocarcinoma; or
    2. Phase 2 only: Stage IIIb/IV NSCLC or other advanced solid tumors with documented positive KRAS or NRAS mutation as determined using a validated test performed in a CAP/CLIA-certified laboratory (or other comparable local or regional certification).
  • Have had disease progression during or following at least 1 and not more than 2 prior lines of treatment for advanced or metastatic disease.
  • Patients with NSCLC must have previously received treatment with an anti-PD-1 or anti-PD-L1 agent for advanced disease.
  • Measurable disease as per RECIST v1.1 criteria.
  • Provision of a baseline tumor sample.
  • Age ?18 years (Japanese patients must be ?20 years old)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
  • Adequate bone marrow, renal and liver functions.
  • Adequate cardiac function.
  • Informed consent provided.

Exclusion Criteria:

  • Prior treatment with avelumab, a PARP inhibitor or MEK inhibitor.
  • Prior systemic anti-cancer therapy within 2 weeks prior to study enrollment.
  • Persisting toxicity related to prior therapy.
  • Current use of immunosuppressive medication.
  • Known history of immune-mediated colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis, uveitis or iritis.
  • Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent.
  • Diagnosis of myelodysplastic syndrome (MDS).
  • Known symptomatic brain metastases requiring steroids.
  • Known history of testing positive for HIV or hepatitis.
  • Clinically significant (ie, active) cardiovascular disease.
  • History of thromboembolic or cerebrovascular events.
  • Current or anticipated use of a P-gp inhibitor, inducer, or inhibitor of breast cancer resistance protein (BCRP)
  • Uncontrolled hypertension.
  • Concurrent neuromuscular disorder that is associated with the potential of elevated creatinine kinase.
  • Known history of Gilbert's syndrome.
  • History or current evidence of retinal degenerative disease, retinal vein occlusion (RVO) or current risk factors for RVO.
  • Other acute or chronic medical or psychiatric condition.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Belgium,   Singapore,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03637491
Other Study ID Numbers  ICMJE B9991033
2018-000124-34 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP